Companies
Gene-Editing Companies by Founding Year
The sector in chronological order — which shows how tightly the founding wave clusters around 2013.
このリストの作り方
Sorting companies by when they were founded shows something striking: a cluster in 2013, immediately after CRISPR was shown to work in human cells, and then successive waves as each new technique arrived — base editing companies around 2017, prime editing from 2019.
| # | エントリー | カテゴリー | Founded | ステータス |
|---|---|---|---|---|
| 1 | Eli Lilly and Company A major pharmaceutical company that entered gene editing by acquisition, buying Verve… | Large pharmaceutical | 1876 | Phase II |
| 2 | Vertex Pharmaceuticals The established biotechnology company that partnered on, and commercialises, the first… | Large biotechnology | 1989 | Approved |
| 3 | Sangamo Therapeutics The company that took gene editing into humans first, years before CRISPR existed as a… | Zinc finger platform | 1995 | Phase III |
| 4 | Caribou Biosciences Co-founded by Jennifer Doudna, using hybrid RNA-DNA guides intended to make editing… | Cell therapy | 2011 | Phase I |
| 5 | CRISPR Therapeutics Co-founded by Emmanuelle Charpentier, and the company behind the first approved CRISPR… | CRISPR-Cas9 platform | 2013 | Approved |
| 6 | Editas Medicine One of the first CRISPR companies, which discontinued its cell-therapy and eye programmes… | In vivo editing | 2013 | Preclinical |
| 7 | Intellia Therapeutics Co-founded by Jennifer Doudna, and the company that first delivered CRISPR into a human… | In vivo CRISPR platform | 2014 | Phase III |
| 8 | Arbor Biotechnologies Co-founded by Feng Zhang and David Scott to discover new editing enzymes from nature at… | Novel editors | 2016 | Phase I |
| 9 | Beam Therapeutics Founded by David Liu and colleagues to commercialise base editing — precision changes to… | Base editing platform | 2017 | Phase III |
| 10 | Mammoth Biosciences Co-founded by Jennifer Doudna around ultra-compact CRISPR proteins small enough to fit… | Miniature editors and diagnostics | 2017 | Preclinical |
| 11 | Sana Biotechnology Engineering transplanted cells to be invisible to the immune system, so they can be given… | Cell engineering | 2018 | Phase I |
| 12 | Scribe Therapeutics Co-founded by Jennifer Doudna to engineer CRISPR enzymes from scratch rather than use the… | Engineered editors | 2018 | Preclinical |
| 13 | Tessera Therapeutics Developing 'gene writing' — mobile genetic elements repurposed to insert whole sequences… | Gene writing | 2018 | Preclinical |
| 14 | Verve Therapeutics Built to turn heart disease into a one-time treatment, and acquired by Eli Lilly in 2025… | In vivo base editing | 2018 | Phase II |
| 15 | Prime Medicine Founded to commercialise prime editing, and the company behind the first published… | Prime editing platform | 2019 | Phase I/II |
| 16 | Tune Therapeutics Turning genes up and down without changing sequence — epigenetic editing taken into early… | Epigenetic editing | 2021 | Phase I |
このリストでわかること・わからないことFounding dates are as reported by the companies. This is not a complete census of the sector.